Alpha Cognition Reports Positive Interim Data for ALPHA-1062 in Military Traumatic Brain Injury Model

Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG), a biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders, today announced promising interim preclinical data supporting the ongoing development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The…

Read MoreAlpha Cognition Reports Positive Interim Data for ALPHA-1062 in Military Traumatic Brain Injury Model

Menarini Group and MEDSIR Unveil Phase III ADELA Study: New Therapy for Advanced Breast Cancer

The Menarini Group, a global leader in pharmaceuticals and diagnostics, and its subsidiary Stemline Therapeutics, focused on delivering innovative oncology treatments, have partnered with MEDSIR, a top independent clinical research organization in oncology and part of Oncoclínicas & Co., the…

Read MoreMenarini Group and MEDSIR Unveil Phase III ADELA Study: New Therapy for Advanced Breast Cancer

Sol-Millennium® Receives Positive Feedback on Needle-Free Insulin Device in Canada

Sol-Millennium® Medical Group, a leading medical device manufacturer, has introduced an innovative needle-free insulin injection device that has garnered widespread acclaim in Canada. This groundbreaking technology aims to enhance the lives of millions of people with diabetes by eliminating the…

Read MoreSol-Millennium® Receives Positive Feedback on Needle-Free Insulin Device in Canada

Swisslog Healthcare Partners with BD to Automate Pharmacy Inventory in US Hospitals

Swisslog Healthcare, a leader in robotic medication management solutions, has partnered with BD, a global medical technology company, to co-market an innovative solution for hospital pharmacies. This collaboration integrates Swisslog’s advanced robotics with BD’s top-tier inventory management and workflow software,…

Read MoreSwisslog Healthcare Partners with BD to Automate Pharmacy Inventory in US Hospitals

Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR® AI platform, announced today the enrollment and dosing of the first patient in Taiwan for its Phase 2 HARMONIC™ clinical trial. The trial is…

Read MoreLantern Pharma Enrolls First Patient in Taiwan for Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC